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Abstract: One of the crucial systems severely affected in several neuromuscular diseases is the loss
of effective connection between muscle and nerve, leading to a pathological non-communication
between the two tissues. The neuromuscular junction (NMJ) represents the critical region at the
level of which muscle and nerve communicate. Defects in signal transmission between terminal
nerve endings and muscle membrane is a common feature of several physio-pathologic conditions
including aging and Amyotrophic Lateral Sclerosis (ALS). Nevertheless, controversy exists on whether
pathological events beginning at the NMJ precede or follow loss of motor units. In this review, the role
of NMJ in the physio-pathologic interplay between muscle and nerve is discussed.
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1. Introduction
1.1. Muscle and Nerve Communication: A Peer to Peer Dialogue at the Neuromuscular Junction
Muscle and nerve communicate at the level of a specialized region, namely the neuromuscular
junction (NMJ), a synaptic connection where the peripheral nervous system contacts skeletal muscle
fibers, governing crucial vital processes, such as body voluntary movements and breathing [1]. Nerve
activity guarantees not only muscle contraction but can induce myoblast orientation [2] and strictly
influences fiber type specification and myosin isoforms expression [3]. Skeletal muscle fibers can
be generally classified as fast or slow twitch, based on their contractile and metabolic properties [4].
These properties are dependent on the pattern of motor nerve stimulation. Tonic motor neuron
activity promotes the slow fiber phenotype, while infrequent motor neuron firing results in fast fibers
generation [5]. Cross reinnervation experiments demonstrated that fast muscles turn into slow ones
when reinnervated by a slow nerve, whereas slow muscles turn into fast ones when reinnervated by
a fast nerve [6,7]. Of note, skeletal muscle is also a source of signals that influence neuron survival,
axonal growth, and maintenance of synaptic connections. Indeed, the development in the absence of
skeletal muscle results in the sequential ablation of motor neurons in the spinal cord and brain [8].
In addition, it has been demonstrated that during the stage of reinnervation the inducible depletion of
adult satellite cells (SCs), the classical muscle stem cell compartment, can impair NMJ regeneration
and affect NMJ morphology [9]. This suggests that skeletal muscle and nerve influence each other
in a functional dialogue that is fundamental for their survival and mechanism of action. The loss of
effective connection between muscle and nerve leads to a pathological non-communication between
the two tissues. In this context, NMJ is the central player of the physiopathologic interplay between
muscle and nerve.
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1.2. Perisynaptic Schwann Cells, a Third Speaker in the Dialogue
NMJ is composed by three major elements: the presynaptic region containing the nerve terminal,
the synaptic cleft, and the postsynaptic surface referred to as the endplate. Several studies have recently
pointed out a critical cellular component in the neuromuscular synapse, namely the synapse-associated
glial cells also called Perisynaptic Schwann Cells (PSCs).
PSCs play an active role in NMJ development and in the maintenance and remodeling of adult
neuromuscular endplate. It has been demonstrated that during development, Schwann cells migrate
in association with growing axons and are located close to NMJ just before muscle-nerve contacts [10].
Moreover, in vivo experiments demonstrated that PSCs increase their number before the period of
synaptic growth and play a guidance role during axon growth and innervation. In contrast, lacks of
PSCs can induce a complete loss of synapses during development or determine pre- and post-synaptic
defects in developing NMJ [11,12].
In adult organisms, PSCs ensure NMJ stability, changing their properties according to the state of
innervation [13]. PSCs provide several trophic molecules, such as agrin, transforming growth factor
beta 1 (Tgf-β1), and Matrix Metalloproteinases (MMPs) that can support muscle-nerve contact and
promote AChR clustering [10,14]. In turn, PSCs are influenced by muscle derived factors, such as NT-3,
Neuregulin-1, or by neuronal released factors, such as ATP, Ach, and neuronal agrin [14].
1.3. Kranocytes Cells, Capping Cells at the NMJ
An additional junctional cell type element, along with skeletal muscle fibers, motor neuron
terminals, perisynaptic terminal Schwann cells, is a fibroblast-like cell, named kranocyte [15]. Kranocyte,
lying outside the synaptic basal lamina, caps the NMJ above the perisynaptic Schwann cells and extends
its cytoplasmic processes over the end-plate area [15,16]. In newborn mouse muscle, kranocytes
are equally distributed, whereas during mouse postnatal development they become restricted at
the endplate zone [15]. Whole mount immunostaining experiments demonstrated an unequivocal
disposition of this subpopulation and elucidated that kranocytes are not Schwann cells. They express a
specific immunocytochemical profile, including collagen-synthetizing enzyme and neuregulin [15].
In this context, kranocytes may interact with terminal Schwann cells through neuregulin mediated
signaling [17].
Although in adulthood kranocytes remain confined at the NMJ region, they play a role in nerve
repair and regeneration after denervation or paralysis. Within 24 h of denervation, kranocytes
proliferate and spread throughout the NMJ area, even before the sprouting of Schwann cells [15,17],
suggesting that this different time of reaction may promote and trigger terminal Schwann cells
outgrowth and activation [15]. Thus, mammalian kranocytes capping cells are integral player of
neuromuscular functionality.
2. ALS and Aging as Paradigmatic Examples of Altered Nerve-Muscle Communication
The impaired neuromuscular transmission represents a critical feature of several pathological
conditions in which structural changes in NMJ might contribute to muscle weakness, altered motor
neuron activity, and loss of muscle fibers.
In this review, we will analyse two extreme physio-pathologic conditions, namely aging and
Amyotrophic Lateral Sclerosis (ALS).
Aging represents a physiologic and progressive decay of the homeostatic processes of the entire
organism and it is broadly defined as the time-dependent functional decline that affects most living
organisms. Common denominators of aging in different organisms include genomic instability, telomere
attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial
dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication [18].
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ALS is a complex and severe disease associated with numerous pathologic mechanisms, including
oxidative stress, mitochondrial dysfunction, axonal damage, microglial activation, inflammation,
excitotoxicity, and protein aggregation [19].
Interestingly, although aging and ALS display different progressive loss of physiological integrity,
they share some common pathologic feature, including high levels of oxidative damage, decreased
number of synaptic vesicles, reduced and altered mitochondria in the plaque region [20–24] (Figure 1).
Moreover, an early pathologic sign observed in both ALS and aging is the morphologic alteration of NMJ.
However, whether changes in the NMJ precede or follow loss of motor units remains unresolved. Here
we detail the NMJ degenerative features in ALS and aging and discuss the paradigm that retrograde
signaling, from muscle to nerve, might represent an early event preceding motor neuron degeneration.
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2.1. Motor Neuron Diseases: ALS
One of the best examples of impaired interplay between nerve and muscle is ALS, a fatal disease
characterized by motor neuron degeneration, muscle atrophy, weakness and, ultimately, muscle
paralysis with respirator failu e. During ALS pr gression muscle den rvation is acco panied
by changes in muscle fiber profile with a preference loss of fast-twitch fiber [25,26], due o higher
vulnerability of fast-fatigable innervating mot r neurons and to specific signals released y PSCs [27].
ALS is epidemiologically classified into two forms: sporadic (90–95%) and familial (5–10%) form.
Among the familial cases, approximately 20% correlate with mutations in the sequence of the Superoxide
Dismutase 1 gene (SOD1), which encodes for an important antioxidant enzyme. In addition to SOD1
mutations, other gene defects have been reported to cause ALS, including senataxin (SETX) [28],
alsin [29,30], dynactin [31], synaptobrevin/VAMP (vesicle-associated membrane protein)-associated
protein B (VAPB) [32], TDP-43, FUS/TLS [33,34], profilin (PFN1) [35], MATR3, CHCHD10, TBK1,
TUBA4A, NEK1, C21orf2, and CCNF [36]. However, even in these cases, where a well-defined mutation
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has been linked to the disease, a clear correlation between the genetic defect and the pathophysiology
of the disease has not yet been disclosed.
Much of what we presently know about the role of mutant genes in ALS is based on studies of
transgenic animals in which the potential genes involved in ALS are overexpressed under the control of
specific promoters. Nevertheless, the failure to translate the positive results obtained in animal models
into successful trials in human has cooled the enthusiasms and raised important questions on the
validity of either animal models or methodological approaches. Thus, robust criteria and guidelines
for preclinical animal research in ALS are necessary [37]. One of the experimental models that has been
widely used in ALS-related studies is the transgenic mutant SOD1 mouse. Although the SOD1 mutant
mice present some limitations compared to ALS patients it remains, along with other ALS-related
mice, an ideal model for preclinical tests and proof-of-concept studies [38]. The obvious loss of motor
neurons in the spinal cord initially focused attention on how mutant SOD1 may act within motor
neurons to provoke neuronal degeneration and death. Among pathogenic events, glutamate-induced
excitotoxicity, oxidative stress, protein aggregation, and mitochondrial dysfunction within motor
neurons have been proposed. However, the mutant gene products are widely expressed, raising
the possibility that the toxic cascade may be achieved wholly or in part by mutant SOD1 action in
non-neuronal cells. Notably, restriction of SOD1 mutant expression selectively to post-natal motor
neurons failed to produce detectable sign of pathology or motor-neuron disease [39], suggesting that
other cell types may be involved in ALS-associated neurodegeneration. Indeed, analysis of chimeras
generated between wild type and SOD1 mutant mouse embryonic cells revealed that wild type non
neuronal cells in adult chimeric animals extended the survival of SOD1 mutant motor neurons [40].
The generation of mouse models expressing human mutated SOD1 gene (SOD1G93A), exclusively
in skeletal muscle, added new insights into the potential primary targets of the mutant SOD1 toxic
protein. Muscle-specific expression of mutant SOD1G93A caused accumulation of reactive oxygen
species (ROS), mitochondria dysfunction, muscle atrophy, NMJ dismantlement, microgliosis [23,41],
and neuron degeneration [42]. All together this evidence suggests that local toxic effect of SOD1G93A is
a primary determinant of ALS-associated muscle pathology and that retrograde signals from muscle
to nerve may contribute, in a sort of dying back phenomenon, to synapse and axon damage [43,44].
In fact, several other recent evidences confirmed the hypothesis that motor neurons are not the only
primary targets of SOD1G93A-mediated toxicity and revealed that early changes of neuromuscular
transmission start long before motor symptoms onset. Fischer and colleagues demonstrated that
pathological changes of motor neuron disease begin at the distal axon and they observed denervation
and reinnervation changes in muscle tissue without any pathological signs in neurons cells [45].
Furthermore, Schafer’s group characterized two different types of motor neurons, the “losers” or
denervated branches, and the “compensators”, or reinnervating branches, which display different
“susceptibility” to the toxic properties of SOD1G93A mutant gene product [46]. Although a conclusive
link is still missing, it is intriguing to speculate that loser and compensator neurons are subject
to different influences from neighboring interneurons, astrocytes, or microglia [40] and from the
vasculature [47,48] and muscle fibers they innervate, all of which might provide either toxic or
protective factors.
This evidence supports the notion that NMJ dismantlement can occur independently from
motor neuron degeneration and may represent an early pathogenic signature of muscle-nerve
communication defects.
2.1.1. PKCθ as a Potential Signaling Involved in NMJ Dysfunction in ALS Disease
It has been demonstrated that Protein Kinase C and A (PKC and PKA) activities have antagonistic
effects on NMJ stability and Acetylcholine Receptors (AChRs) recycling [49]. Stimulation of PKC
or inactivation of PKA significantly accelerates the removal of postsynaptic AChRs and depresses
AChR recycling. A recent work disclosed the PKC isoform, namely PKCθ, which triggers NMJ
dismantlement in a mouse model expressing SOD1G93A mutant gene. PKCθ is a kinase that triggers
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in physiological condition the dismantlement of supernumerary NMJs during the first postnatal
days [23,50]. It has been demonstrated that perturbation in redox signaling cascades, induced by
muscle-specific accumulation of mutant SOD1G93A gene, promotes the activation of PKCθ that in
turn acts as mediator of endplates destabilization [23]. In contrast, PKCθ selective pharmacological
inhibition reduces oxidative damage and guarantees the stabilization of AChR turnover and the rescue
of the NMJ morphological complexity [23].
PKCθ also modulates the activation of two sensors of nerve activity, Calcineurin (CN) and
Nuclear Factor of Activated T cells (NFATc1), which promote slow muscle phenotype through
the activation of their target Myocyte Enhancer Factor 2D (MEF2D), involved in muscle glucose
homeostasis. Furthermore, it has been demonstrated that PKCθ-lacking mice display an impaired
glucose homeostasis in fast muscles [51,52], suggesting that PKCθ can participate to muscle metabolic
changes associated to muscle denervation and ALS disease progression.
2.1.2. Metabolic Changes and Mitochondrial Alteration May Influence NMJ Stability
Metabolic homeostasis and energy balance result severely compromised in both ALS patients
and mouse models, where the energy expenditure is higher than the intake and it is associated to an
increased energy demand and to an abnormal lipid metabolism [53–57]. In fact, a recent study revealed
that ALS patients start losing weight almost 10 years before the clinical onset of the disease and show a
higher daily energy intake to compensate the elevated energy consumption [58]. Likewise, the ALS
mouse model that ubiquitously overexpress SOD1G93A mutant gene shows similar energetic alterations,
such as an increased energy expenditure and a concomitant skeletal muscle hypermetabolism [59].
Further evidence has also pointed out that metabolic alterations in SOD1G93A mouse model can
be distinct from denervation [60] and that muscle specific accumulation of SOD1G93A is able to induce
metabolic changes in glucose and lipid pathways, independently from motor neuron degeneration
and preceding muscle denervation [61]. These data suggest that some of the metabolic changes
represent part of the earliest signs of morphological and functional alterations occurring in the motor
nerve terminals. Among cell components, dysfunctional mitochondria represent key regulators of
metabolic changes [62–65]. Indeed, treatment with mitochondria protective drug can preserve NMJ
function and structure in ALS mouse model at late stages of the disease, suggesting a central role of
mitochondria in the pathology [66]. The link between muscle functional mitochondrial alterations and
neurodegeneration has been clarified by Dupuis and collaborators. The analysis of a transgenic mouse
model overexpressing the potent mitochondrial uncoupler protein (UCP1) exclusively in skeletal
muscle revealed that muscle specific expression of UCP1 induces an age-dependent deterioration of
the NMJ [67]. This defect correlated with progressive signs of denervation, supporting the idea of the
crucial role of skeletal muscle on nerve homeostasis and revealing the potential molecular signature
associated with the dying back phenomenon [67].
It has been demonstrated that antioxidant treatment of mice expressing human mutated SOD1
gene (SOD1G93A) exclusively in skeletal muscle was able to rescue mitochondrial functionality and
NMJ stability [23,41]. Moreover, studies on SOD1G93A mice overexpressing the neurotrophic factors
GDNF or IGF-1 in muscle tissue revealed an hyperinnervation of muscle fibers [68–76], NMJ stability,
and motor neuron preservation [40,44,47]. This suggests that a sort of “saving back” approach
can be envisaged. Nevertheless, not all treatments guarantee the same efficacy. Neuromuscular
Magnetic Stimulation (NMMS) was able to induce a significant increase of muscle strength, without
significant change in Compound Muscle Action Potential (CMAP) amplitude, suggesting that the
improvement was not related to reinnervation phenomena [77]. In particular, NMMS activated a
molecular mini-circuit to counteract muscle atrophy, to promote muscle robustness and maintenance of
fiber type composition, and to induce NMJ stabilization. In addition, NMMS induced an improvement
of AChR functionality, characterized by the reduction of the expression level of gamma subunit of
AChR [77], whose expression increases in denervated muscle or under conditions that alter NMJ
functionality [23,78].
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It has been also demonstrated that Musk activation preserves synapses at the NMJ in diaphragm
muscles of mutant SOD1 transgenic mice, without any positive effects on motor neuron death
and survival [79]. Cleveland and colleagues demonstrated that the over expression of Peroxisome
proliferator-activated receptor-gamma coactivator (PGC)-1alpha in the skeletal muscle of ALS transgenic
mice is able to increase mitochondria energy production, ameliorating muscle endurance and
performance and reducing muscle atrophy, without any effects on muscle innervation and motor neuron
survival [80]. Nevertheless, the authors did not detail NMJ morphology in PGC1α overexpressing
ALS mice even if it has been demonstrated that muscle-specific PGC-1α expression induces functional
improvement in NMJ [81]. These data suggest that additional work is necessary to define the best
experimental conditions to support a “saving back” therapeutic approach. Moreover, all these data
reinforce the evidence that ALS is a complex multi-systemic disease in which alterations in structural,
physiological and metabolic parameters in different cell types, including motor neurons, glia, NMJ,
vasculature, and muscle, act synergistically to exacerbate the disease. Moreover, all these works suggest
that a single treatment or the modulation of a single pathway may be not enough to significantly
counteract motor neuron degeneration and increase survival. Combinatorial approaches on different
tissue targets might be necessary to achieve satisfactory therapeutic benefits.
2.2. Aging and NMJ Defect
Another physio-pathologic condition where the functional communication between muscle and
nerve is compromised is aging. As mammals grow older, many functional and structural changes
occur in skeletal muscle and NMJ, leading to gradual loss of mobility [82].
It is widely accepted that not all muscles share the same susceptibility to age-related alterations.
Several studies indicate diversity in muscle fibers susceptibility to the denervation process, based on
motor neuron type. The NMJ associated with faster-contracting motor neurons are more susceptible to
age-related structural changes than those associated with slower-contracting motor neurons [83–85].
One of the first evidences of the aging process occurring in NMJ is the formation of new branches
of terminal axons that form new synaptic sites on muscle fibers [82]. NMJ undergo remodeling
processes with cyclical extension and retraction of motor nerve terminals, leading to an increase
in the complexity of the nerve terminal arborization [82]. In particular, this remodeling process is
characterized by the increase in size and complexity of the branches of terminal axons [86], associated
with fragmentation [87–95] and folds reduction of postsynaptic sites [90,96]. It has been demonstrated
that oxidative stress, along with compromised mitochondria and increased intracellular calcium,
amplifies the presynaptic decline in NMJ, accompanied with a decreased number of synaptic vesicles,
similarly to what observed in ALS mouse models [23,91,97]. This initial NMJ dysfunction is followed by
a neurodegeneration promoted by increased production of inflammatory cytokines and loss of trophic
support [97]. Moreover, the evidence that some denervated fibers are not successfully re-innervated
during aging raise the prospect that this alteration is at the base of the progressive decline in muscle
mass and strength with aging, a condition known as sarcopenia.
The triggers of the NMJ alterations during aging are still debated. It is still unclear whether
NMJ changes in aged muscles are caused by alterations in motor neurons or rather in skeletal muscle
fiber [98]. One of the possible causes is the death of a fraction of motor neurons, occurring in
humans between the age of 60 and 90 [99]. It has been suggested that motor neuron death provokes
a temporary denervation of downstream muscles and induces a collateral reinnervation process.
This process is driven by Perisynaptic Schwann cells that grow from the axon stump to guide surviving
motor neurons that sprout their axons to create new synaptic terminals on muscle fibers [100,101].
Nevertheless, in advanced age, motor neurons show impaired capacity to re-innervated denervated
fibers, suggesting that alterations in different components of nerve-muscle circuit impinge the potential
compensatory mechanisms.
Other studies suggest that changes in the end-plate morphology and NMJ remodeling that occur
with aging precede the loss of fast motor units and suggest the involvement of retrograde signaling.
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It has been reported that proteolytic cleavage of agrin, a proteoglycan involved in NMJ development,
maturation, and AChRs clustering [102], induces early onset sarcopenia in young adult mice [103],
whereas the injection of a neurotrypsin-resistant agrin fragment stabilized NMJ and improved the
phenotype of neurotrypsin-overexpressing mice [104].
Other studies employed the effect of Muscle Electrical Stimulation (ES) to improve muscle
functionality and to counteract NMJ decline during aging [105]. ES treatment in old sedentary
people improved muscle performance, increasing fiber size, stimulating satellite cells and modulating
the degeneration of the mitochondrial apparatus [106,107]. Moreover, it has been reported that ES
treatment increases the number of fast twitch fibers [108] and counteracts neuromuscular disabilities
from age related NMJ degeneration in paraplegic patients [109,110]. At molecular level ES treatment
activates signaling pathways that decode for a specific calcium signaling involved in metabolic and
structural adaptation of muscle fibers, such as the Calcineurin-NFAT and CamKII pathways that
control the maintenance or switching of muscle fiber type [108]. Moreover, it has been described that
biphasic electrical stimulation significantly increases the number and size of AChRs clusters available
for NMJ formation during innervation [105] and that electrical stimulation promotes axonal growth
and sensorimotor functional recovery after injury [106].
Factors that Influence NMJ Stability during Aging
Among the factors that can affect the stability of the NMJ there are metabolic changes associated
to mitochondrial dysfunction and lifestyle.
Several recent evidence demonstrated that mitochondrial energy metabolism is altered during
muscle aging, which is also accompanied by a reduction in the rate of oxygen consumption [107,111].
In human skeletal muscle, as well as in animal models, the mitochondrial capability to produce ATP
decreases with age [112–118].
It is widely recognized that mitochondrial dysfunctions have a causal link with cellular ROS
accumulation and therefore, as organisms grow old, there is an increase of intracellular ROS and
consequently an accumulation of damaged cell components in all the tissues [119]. Since muscle and
nerve are highly metabolic active tissues, their mutual communication is affected by mitochondrial
dysfunction.
Another factor playing a crucial role in sarcopenia progression is lifestyle. Physical inactivity and
impaired nutrition stimulate loss of muscle mass and NMJ defect, exacerbating sarcopenia [120,121].
It has been demonstrated that exercise induces muscle hypertrophy and NMJ remodeling, and improves
recovery of peripheral nervous terminal after nerve injury [122,123]. In old mice exercise training is
able to minimize NMJ expansion that turn back to levels comparable to young mice [124].
How skeletal muscle and NMJ send retrograde signals to motor neurons represents an intriguing
field of research. Skeletal muscle has been identified as an endocrine organ that produce and secrete
growth factors, cytokines, and peptides, collectively indicated as myokines, which make muscle
capable to communicate with other tissues and organs, including bone, intestine, adipose tissue,
liver, pancreas, and brain [125]. One of the critical players that integrates muscle fiber function
with motor neuron signaling following exercise is Peroxisome proliferator-activated receptor-gamma
coactivator (PGC)-1alpha. PGC-1α expression activates a broad NMJ gene program and improves
postsynaptic NMJ architecture [81,126]. It has been demonstrated that loss of skeletal muscle PGC-1α
hampers acetylcholine receptor (AChR) clustering and the transcription of NMJ genes including
AChRs, muscle-specific kinase, and utrophin [126].
Among other factors, Insulin-like Growth Factor-1 (IGF-1) plays a pivotal role in muscle growth,
differentiation, and regeneration [127,128]. In mammalian organisms the majority of IGF-1 is produced
and released by the liver as systemic growth factor, while a minor fraction is produced by other tissues
and participates to autocrine and paracrine signals. In skeletal muscle, the binding of IGF-1 with
its receptor activates anabolic, anticatabolic, and antiapoptotic signaling pathways that preserves
muscle mass and strength [129]. It has been demonstrated that the overexpression of IGF-1 isoforms
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selectively in skeletal muscle maintains muscle mass and activates several pathways that promote the
clearance of dysfunctional mitochondria and the maintenance of NMJ stability in senescence mice [130].
Moreover, it has been demonstrated that IGF-1 overexpression is sufficient to downregulate the levels
of two cytokines, namely IL-1β and IL-6, in aged mice, counteracting the chronic inflammation process
typical of aging (inflammaging) [130]. In this context, a crucial role is played by senescent Schwann
cells that overexpress IL-6 cytokine and negatively affect the nerve microenvironment during muscle
innervation [131].
3. Conclusions
Significant advances have been provided in the understanding the critical components involved
in aging and ALS. Morphological and functional alterations of the NMJ represent part of the earliest
signs of aging and ALS. Nevertheless, no consensus has emerged to the cells, tissues, and pathways
that are directly affected. Although several pieces of the aging and ALS pathogenic puzzles have
been defined, the picture of these diseases remained to be completed. The field will benefit when the
pathologic events, the factors, the cell and tissue components, and the late “restriction point”, which
might trigger the final catastrophic event, will be sequentially characterized. This will also help to:
(i) verify whether a sort of “saving back” approach can be envisaged and tested and to (ii) design more
effective therapeutic approaches, acting in a timely fashion on the different cells and tissues involved
in the diseases (Figure 2).
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